Publications by authors named "C Bachert"
Article Synopsis
- Pivotal studies have shown that dupilumab significantly improves nasal polyp scores, symptom scores, and overall quality of life in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
- A large-scale evaluation at six European centers found that after 24 and 52 weeks of treatment, patient outcomes consistently improved, regardless of demographic factors or prior treatments.
- By the end of the study, a substantial percentage of the patients met improved health criteria, indicating that dupilumab remains effective over time and not influenced by previous sinus surgeries or other major health issues.
Article Synopsis
- Alphaherpesviruses like HSV-1, pseudorabies virus (PRV), and bovine herpesvirus (BoHV-1) are important pathogens that invade the respiratory tract, but the specifics of how they penetrate mucosal barriers are still unclear.
- This study focuses on the gE/gI glycoprotein complex and proteases, finding that removing calcium from the environment enhances viral infection by breaking down epithelial junctions and suggesting a shared method for how these viruses target their receptors.
- Results showed that PRV replicates faster and invades deeper than HSV-1 and BoHV-1, with the gE glycoprotein being crucial for viral entry, while specific proteases contribute differently to invasion among
Mild and symptom-free months in patients with chronic rhinosinusitis with nasal polyps treated with dupilumab.
Ann Allergy Asthma Immunol
January 2025
Background: Frequently reported outcomes of clinical trials in chronic rhinosinusitis with nasal polyps (CRSwNP) may have limited relatability for patients.
Objective: To enhance the patient relatability of outcomes in dupilumab clinical trials for CRSwNP, daily symptom scores were used to determine new patient‑centered end points: mild-to-no-symptom months (MSM) and symptom-free months (SFM).
Methods: This work is a post hoc analysis of patients receiving dupilumab 300 mg or placebo every 2 weeks for 24 weeks (SINUS-24 study; NCT02912468) or 52 weeks (SINUS‑52; NCT02898454).
Background: Dupilumab and mepolizumab have shown efficacy and safety in treating chronic rhinosinusitis with nasal polyps (CRSwNP).
Objective: Without available results from head-to-head randomized control trials (RCTs) comparing dupilumab with other biologics, we conducted an indirect treatment comparison (ITC) with mepolizumab.
Methods: A systematic literature review identified RCTs of biologics in CRSwNP.
Background: The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact of comorbid upper and lower airway disease and blood eosinophil count (BEC) on sleep-/fatigue-related outcomes in CRSwNP.
Methods: This was an analysis of the Phase III SYNAPSE and MUSCA (NCT03085797/NCT02281318) trials of mepolizumab in patients with severe CRSwNP and severe asthma, respectively.